Tag Archives: amgn

Regeneron, Amgen Downgraded As Biotech Seen Slowing

UBS downgraded Regeneron (REGN) and Amgen (AMGN) and adjusted the price targets on several other biotech stocks Thursday on the grounds that the sector may be in for a slow patch. “Although we still think that biotech will continue to outperform the broader markets and the Health Care SPDR (XLV), we are getting more selective with our price targets and ratings considering fewer near-term catalysts with the power to drive material upward revisions

Amgen Cholesterol Drug Repatha Wins FDA Panel Vote

An FDA advisory committee voted in favor of approving Amgen’s (AMGN) cholesterol drug Repatha Wednesday afternoon, but voiced similar concerns as it did for Regeneron’s (REGN) and Sanofi’s (SNY) fellow PCSK9 inhibitor Tuesday. Still, Amgen stock was up about 1% in after-hours trading Wednesday after rising a fraction in the regular session. The panel voted 11-4 in favor of approving Repatha for patients with heterozygous familial

Regeneron, Amgen Fall On Cholesterol Drug Worries

Big biotech Regeneron Pharmaceuticals (REGN) was down nearly 5% Wednesday as Wall Street digested the impact of an ambiguous FDA advisory committee vote on its cholesterol drug Praluent late Tuesday. Meanwhile, rival Amgen (AMGN) was off 2% as the committee reconvened to vote on its similar drug Repatha. The panel endorsed approval overall, but the caution around the real connection between lower LDL cholesterol and cardiovascular health raised